Valeant Pharmaceuticals International VRX
The three reasons
- 1
Citron's 'next Enron' channel-stuffing claim is verifiably false; Philidor accounting is conservative
- 2
Even assuming Philidor sales are fully lost, VRX trades at only ~8x 2016 Cash EPS
- 3
Long-term model implies 135%-214% upside; echoes Buffett's 1963 AmEx Salad Oil buy
Primary demands
- Hold/accumulate VRX despite Citron report and Philidor controversy
- Demand greater transparency and disclosure from Valeant management
- Support termination of Philidor relationship and development of new channel partners
- Await completion of ad hoc board committee review of Philidor compliance
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Notable slides (8)
Notes
Specimen of the 'activist-long defense' genre: Pershing defending its ~16.5mm share VRX position after Citron Research's Oct 21, 2015 'next Enron' short report triggered a crash from $260 to $111. Distinctive structure: (1) annotated share-price timeline establishing cause-effect of news events, (2) point-by-point rebuttal of specialty-pharmacy/channel-stuffing allegations, (3) Novartis precedent reassuring that specialty-pharmacy issues are survivable, (4) conservative valuation cases (even with full Philidor loss), (5) historical analogy to Buffett's 1963 AmEx Salad Oil trade as the rhetorical climax. Filename year (2014-09) is misleading — deck is clearly dated October 30, 2015. Campaign ultimately failed: Pershing exited Valeant in March 2017 at a ~$4bn loss, making this a canonical case of a contrarian defense that was on the wrong side. Note the Buffett-fearful-when-others-greedy closer is almost a meta-tell. Strong narrative specimen, modest visual craft.